Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (648)	12/1/1998 1:24:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

Dan, people just read the Reuters headlines (which is scary when taken out of context and without the background in the other newswires), and possibly skim through the article and decide that they'll sell, that Celebrex won't be approved... MRK's up - the rationale is that Vioxx would be approved first, would then be the first Cox-2 inhibitor out. Who would bother to read everything before selling! Perhaps I'd be proven wrong, but I still feel that Celebrex would be given a recommendation by the Adv. panel tomorrow. We'll know tomorrow. PFE's volume is still not higher than the average daily volume. This is going to be as important to PFE as it is to MTC.